MannKind Corporation to Participate in H.C. Wainwright Bioconnect Conference
05 janv. 2022 06h10 HE
|
MannKind
DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with...
MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases
05 janv. 2022 06h05 HE
|
MannKind
MannKind purchased an additional convertible note issued by Thirona BioNonclinical PD study of MNKD-501 planned, with results anticipated in 2Q 2022MannKind’s CEO appointed as a member of the Thirona...
MannKind Corporation to Participate in the Lytham Partners Winter 2021 Investor Conference
06 déc. 2021 06h05 HE
|
MannKind
WESTLAKE VILLAGE, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for...
MannKind Corporation Reports 2021 Third Quarter Financial Results
09 nov. 2021 16h05 HE
|
MannKind
Conference Call to Begin Today at 5:00 p.m. (ET) 3Q 2021 Total Revenues of $22.2 million; +45% vs. 3Q 20203Q 2021 Afrezza Net Revenue of $9.8 million; +34% vs. 3Q 2020$181.1 million of Cash, Cash...
Mannkind Corporation Closes Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds
09 nov. 2021 06h05 HE
|
MannKind
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Nov. 09, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
MannKind Presents Data at 21st Annual Diabetes Technology Meeting
05 nov. 2021 07h05 HE
|
MannKind
A Technosphere® Insulin (TI) dose – approximately double the estimated mealtime subcutaneously (SC) injection dose – reduced postprandial glucose excursions (PPGE) without any severe hypoglycemia in...
MannKind Corporation to Hold 2021 Third Quarter Financial Results Conference Call on November 9, 2021
02 nov. 2021 06h05 HE
|
MannKind
WESTLAKE VILLAGE, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2021 third quarter financial results and its management will host a conference call to...
Progress Update on Tyvaso DPI™ New Drug Application
18 oct. 2021 06h00 HE
|
MannKind
Complete response received by United Therapeutics cites an open inspection issue at a third-party analytical testing center; no other deficiencies citedNo issues identified regarding operations...
MannKind Announces First Patient Enrolled in INHALE-1 Study of Afrezza® in Pediatric Population
04 oct. 2021 07h05 HE
|
MannKind
WESTLAKE VILLAGE, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for...
Mannkind Corporation Announces Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds
29 sept. 2021 16h24 HE
|
MannKind
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Sept. 29, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...